medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2022, Number 2

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2022; 20 (2)

Permanent taxane-induced alopecia: A case report and review

Ruiz GD, Briseño GG, Leal OSE

Language: Spanish
References: 34
Page: 185-190
PDF size: 601.63 Kb.


ABSTRACT

Alopecia secondary to chemotherapy is a common adverse effect in cancer patients. It’s usually reversible, however, there is an increase in reports of permanent alopecia, especially in breast cancer patients receiving taxane therapy. The pathophysiology is not well defined, but the findings are similar to those found in androgenetic alopecia. We present the case of a 47 years old female patient diagnosed with breast cancer that presents with permanent alopecia secondary to paclitaxel and a review of the literature.


REFERENCES

  1. Zielinski C, Beslija S, Mrsic-Krmpotic Z et al., Gemcitabine, epirubicin,and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamideas first-line chemotherapy in metastatic breast cancer: a Central EuropeanCooperative Oncology Group international, multicenter, prospective,randomized phase iii trial, J Clin Oncol 2005; 23:1401-8.

  2. Kim IR, Cho JH, Choi EK et al., Perception, attitudes, preparedness andexperience of chemotherapy-induced alopecia among breast cancerpatients: a qualitative study, Asian Pac J Cancer Prev 2012; 13:1383-8.

  3. McGarvey EL, Baum LD, Pinkerton RC et al., Psychological sequelaeand alopecia among women with cancer, Cancer Pract 2001; 9:283-9.

  4. Slaught C, Roman M, Yashar S, Holland V y Goh C, Permanent alopeciain breast cancer patients: role of taxanes and endocrine therapies,Cutis 2021; 107(3):17-22.

  5. Sibaud V, Leboeuf NR, Roche H, Belum VR, Gladieff L, Deslandres Met al., Dermatological adverse events with taxane chemotherapy, Eur JDermatol 2016; 26(5):427-43.

  6. Corazza M, Minghetti S, Borghi A, Virgili A y Ballardini P, Hand-footsyndrome caused by docetaxel with no recurrence after switch topaclitaxel, a different taxane, Int J Dermatol 2014; 53(3):e180-2.

  7. Harris CS, Wang D y Carulli A, Docetaxel-associated palmarplantarerythrodysesthesia: a case report and review of the literature, J OncolPharm Pract 2014; 20:73-80.

  8. Minisini AM, Tosti A, Sobrero AF, Mansutti M, Piraccini BM, Sacco C yPuglisi F, Taxane-induced nail changes: incidence, clinical presentationand outcome, Ann Oncol 2003; 14(2):333-7.

  9. Robert C, Sibaud V, Mateus C, Verschoore M, Charles C, Lanoy E et al.,Nail toxicities induced by systemic anticancer treatments, Lancet Oncol2015; 16(4):e181-9.

  10. Paus R, Haslam IS, Sharov AA y Botchkarev VA, Pathobiology of chemotherapy-induced hair loss, Lancet Oncol 2013; 14(2):e50-9.

  11. Kluger N, Jacot W, Frouin E, Rigau V, Poujol S, Dereure O et al., Permanentscalp alopecia related to breast cancer chemotherapy by sequentialfluorouracil/epirubicin/cyclophosphamide (fec) and docetaxel: aprospective study of 20 patients, Ann Oncol 2012; 23(11):2879-84.

  12. Chan J, Adderley H, Alameddine M, Armstrong A, Arundell D, Fox R,Harries M et al., Permanent hair loss associated with taxane chemotherapyuse in breast cancer: a retrospective survey at two tertiary UKcancer centres, Eur J Cancer Care (Inglaterra) 202; 30(3):1-7.

  13. Bourgeois H, Denis F, Kerbrat P, Combe M, Lamy R, Egreteau J etal., Long term persistent alopecia and suboptimal hair regrowth afteradjuvant chemotherapy for breast cancer: alert for an emerging sideeffect: alopers Observatory, Cancer Res 2009; 69-78.

  14. Kang D, Kim IR, Choi EK, Im YH, Park YH, Ahn JS, et al., Permanent chemotherapy-induced alopecia in patients with breast cancer: a 3-yearprospective cohort study, Oncologist 2019; 24(3):414-20.

  15. Freites-Martínez A, Chan D, Sibaud V, Shapiro J, Fabbrocini G, TostiA et al., Assessment of quality of life and treatment outcomes ofpatients with persistent postchemotherapy alopecia, jama Dermatol2019; 155(6):724-8.

  16. Prevezas C, Matard B, Pinquier L y Reygagne P, Irreversible and severealopecia following docetaxel or paclitaxel cytotoxic therapy for breastcancer, Br J Dermatol 2009; 160(4):883-5.

  17. Masidonski P y Mahon SM, Permanent alopecia in women beingtreated for breast cancer, Clin J Oncol Nurs 2009; 13:13-4.

  18. Saggar V, Wu S, Dickler MN y Lacouture ME, Alopecia with endocrinetherapies in patients with cancer, Oncologist 2013; 18(10):1126-34.

  19. Fonia A, Cota C, Setterfield JF, Goldberg LJ, Fenton DA y StefanatoCM, Permanent alopecia in patients with breast cancer after taxanechemotherapy and adjuvant hormonal therapy: clinicopathologicfindings in a cohort of 10 patients, J Am Acad Dermatol 2017; 76(5):948-7.

  20. Werbel T y Cohen PR, Persistent alopecia in a breast cancer patientfollowing taxane chemotherapy and adjuvant endocrine therapy: casereport and review of post-treatment hair loss in oncology patientswith breast cancer, Cureus 2018; 10(7):3056-62.

  21. Tallon B, Blanchard E y Goldberg LJ, Permanent chemotherapy-inducedalopecia: case report and review of the literature, J Am AcadDermatol 2010; 63:333-6.

  22. Miteva M, Misciali C, Fanti PA, Vincenzi C, Romanelli P y Tosti A, Permanentalopecia after systemic chemotherapy: a clinicopathologicalstudy of 10 cases, Am J Dermatopathol 2011; 33(4):345-50.

  23. Tallon B, Blanchard E y Goldberg LJ, Permanent chemotherapy-inducedalopecia: histopathologic criteria still to be defined, J Am AcadDermatol 2013; 68:151-2.

  24. Kanti V, Nuwayhid R, Lindner J, Hillmann K, Stroux A, BangemannN, Kleine-Tebbe A, Blume-Peytavi U y García Bartels N, Analysis ofquantitative changes in hair growth during treatment with chemotherapyor tamoxifen in patients with breast cancer: a cohort study,Br J Dermatol 2014; 170(3):643-50.

  25. Bhoyrul B, Asfour L, Lutz G, Mitchell L, Jerjen R, Sinclair RD et al., Clinicopathologiccharacteristics and response to treatment of persistentchemotherapy-induced alopecia in breast cancer survivors, jama Dermatol2021; 157(11):1335-42.

  26. Rubio-González B, Juhász M, Fortman J y Mesinkovska NA, Pathogenesisand treatment options for chemotherapy-induced alopecia: asystematic review, Int J Dermatol 2018; 57(12):1417-24.

  27. Rozner RN, Freites-Martínez A, Shapiro J, Geer EB, Goldfarb S yLacouture ME, Safety of 5α-reductase inhibitors and spironolactonein breast cancer patients receiving endocrine therapies, Breast CancerRes Treat 2019; 174(1):15-26.

  28. Yang X y Thai KE, Treatment of permanent chemotherapy-inducedalopecia with low dose oral minoxidil, Australas J Dermatol 2016;57(4):130-2.

  29. Wei C, Bovonratwet P, Gu A, Moawad G, Silverberg JI y FriedmanAJ, Spironolactone use does not increase the risk of female breastcancer recurrence: a retrospective analysis, J Am Acad Dermatol 2020;83(4):1021-27.

  30. Heymann WR, Spironolactone and breast cancer: Fear not!, J Am AcadDermatol 2020; 83(4):1008-9.

  31. Sabatier P, Amar J, Montastruc F, Rousseau V, Chebane L, Bouhanick Bet al., Breast cancer and spironolactone: an observational postmarketingstudy, Eur J Clin Pharmacol 2019; 75(11):1593-98.

  32. Barrón-Hernández YL y Tosti A, Bimatoprost for the treatment ofeyelash, eyebrow and scalp alopecia, Expert Opin Investig Drugs 2017;26:515-22.

  33. Bouhanna P, Larif M y Guichard A, Hair transplantation in endocrinetherapy-induced alopecia, Dermatol Surg 2021; 47(3):438-40.

  34. Quesada S, Guichard A y Fiteni F, Cancer-related alopecia: from etiologiesto global management, Cancers (Basilea) 2021; 13(21):55-56.




2020     |     www.medigraphic.com